目的 系統(tǒng)評價升降散聯(lián)合西醫(yī)常規(guī)治療膿毒癥的有效性和安全性。方法 計算機(jī)檢索中國學(xué)術(shù)期刊全文數(shù)據(jù)庫（CNKI）、萬方數(shù)據(jù)知識服務(wù)平臺（Wanfang Data）、維普中文期刊全文數(shù)據(jù)庫（VIP）、PubMed、Cochrane Library、Embase、Web of Science數(shù)據(jù)庫中升降散治療膿毒癥的隨機(jī)對照試驗（RCT），借助RevMan 5.4軟件進(jìn)行Meta分析。結(jié)果 共納入13項RCTs，共720例患者。Meta分析結(jié)果表明，試驗組（加用升降散）與對照組（西醫(yī)常規(guī)治療）比較，可提高中醫(yī)證候療效［OR＝7.04，95% CI（2.85，17.35），P<0.000 01］，降低中醫(yī)證候積分［MD＝-1.50，95% CI（-1.97，-1.04），P<0.000 01］、急性生理與慢性健康評分［MD＝-2.56，95% CI（-3.64，-1.49），P<0.000 01］、白細(xì)胞計數(shù)［MD＝-1.57，95% CI（-2.14，-1.00），P<0.000 01］、C反應(yīng)蛋白水平［MD＝-10.01，95% CI（-15.51，-4.52），P＝0.000 4］，腫瘤壞死因子-α水平［MD＝-7.41，95% CI（-13.22，-1.61），P＝0.01］、白細(xì)胞介素-6水平［MD＝-7.71，95% CI（-13.92，-1.50） ，P＝0.01］，表明升降散在改善癥狀和降低炎癥方面有顯著優(yōu)勢；在安全性方面，兩組比較無統(tǒng)計學(xué)差異。結(jié)論 升降散治療膿毒癥的療效顯著，可降低炎癥反應(yīng)，且安全性較高，適用于臨床聯(lián)合用藥。

Objective To systematically evaluate the efficacy and safety of Shengjiang Powder combined with conventional western medicine in the treatment of sepsis. Methods Databases such as CNKI, Wanfang Data, VIP, PubMed, Cochrane Library, Embase, and Web of Science were searched by computer for the randomized controlled trial (RCT) of Shengjiang Powder in the treatment of sepsis, the data was analyzed with RevMan 5.4 software. Results A total of 13 RCTs were included, including 720 patients. Metaanalysis results showed that adding to Shengjiang Powder conventional western medicine treatment improved curative effect of traditional Chinese medicine (TCM) syndrome[OR=7.04, 95%CI (2.85, 17.35), P < 0.000 01], reduced the TCM syndrome score[MD=-1.50, 95%CI (-1.97,-1.04), P < 0.000 01], acute physiology and chronic health score[MD=-2.56, 95%CI (-3.64,-1.49), P < 0.000 01], WBC count[MD=-1.57, 95%CI (-2.14,-1.00), P < 0.000 01], C-reactive protein level[MD=-10.01, 95%CI (-15.51,-4.52), P＝0.000 4], tumor necrosis factor-α level[MD=-7.41, 95%CI (-13.22,-1.61), P＝0.01], interleukin-6 level[MD=-7.71, 95%CI (-13.92,-1.50), P＝0.01], indicators are statistically significant, indicating that Shengjiang Powder has significant advantages in improving symptoms and reducing inflammation. There was no statistical difference in safety between the two groups. Conclusion Shengjiang Powder is effective in the treatment of sepsis, which can reduce the inflammatory reaction of sepsis and has high safety, so it is suitable for clinical combined use.

R287.5

國家重點研發(fā)計劃項目（2018YFC1707503）；天津市中醫(yī)藥重點領(lǐng)域科研項目（2021010）；天津市衛(wèi)生健康委、天津市中醫(yī)藥管理局中醫(yī)中西醫(yī)結(jié)合科研課題（2021098）